At a Glance
- Company: Harbour BioMed; partner: Solstice Therapeutics
- Location: Harbour BioMed (Hong Kong/Shanghai); Solstice undisclosed
- Deal value: $1.1B total (upfront + milestones + royalties)
- Focus area: Undisclosed biologic/immunology assets
- Next steps: Option exercise, clinical development acceleration
What happened?
Harbour BioMed announced a global licensing and collaboration agreement with Solstice Therapeutics valued at up to $1.1 billion in biobucks. The deal grants Solstice exclusive rights to advance undisclosed assets from Harbour’s antibody platform, with Harbour receiving upfront payments, development/regulatory milestones and tiered royalties on sales. Terms position this as a major validation of Harbour’s discovery capabilities.
Why does it matter?
Biobucks deals provide non-dilutive funding critical for mid-sized biotechs to progress pipelines without heavy equity raises. For Harbour BioMed, the $1.1B potential underscores growing big pharma interest in Asian-sourced antibodies, especially in immunology where Harbour excels. Solstice gains high-potential assets to bolster its portfolio amid competitive pressure for differentiated therapies.
Who’s behind it?
Har Harbour BioMed, a clinical-stage biotech with a fully integrated antibody platform (HBMX tech), has a track record of multimodality partnerships. Solstice Therapeutics, likely a well-resourced player in immunology or oncology, leverages the deal for pipeline expansion. Leadership from both sides highlighted strategic alignment.
How was it achieved?
The agreement covers exclusive worldwide rights (ex-China for Harbour) to select assets, likely monoclonal antibodies targeting high-value indications. Deal structure includes near-term upfront cash, escalating milestones tied to clinical proof-of-concept through commercialisation, plus double-digit royalties—standard for preclinical-to-early clinical handoffs.
What’s next?
Solstice initiates or accelerates clinical studies on opted assets; Harbour retains certain regional rights and gains funding for internal programmes. Potential data readouts in 12-18 months could trigger first milestones, with commercialisation eyed for late 2020s.